Lower Middle Market Businesses for Sale in Indiana

1. Fourth-generation farmers operating a 3-acre greenhouse in Francisville, selling to leading Midwest grocery retailers. 2. Product and services include organic potted living herbs, organic cut herbs, organic potted wheatgrass, Hydro Basil, and retail and bulk baby-leaf lettuces. 3. Strong year on year revenue and margin growth, with industry-leading order fill rates and very low product rejections. 4. Expanding reach with new value-add products to increase margin and exposure with retailers. 5. Organic and sustainable production in a safe and environmentally friendly environment. 6. Innovative technologies and techniques for optimal growth and crop yield. 7. Unique family-run business with over 10 years of experience in the industry. 8. We are currently operating at a loss.

- Anderson, US based company that has been operational for over 13 years. - Company has designed and developed two types of 4 wheeler wheelbarrows to transport materials in a different way. - We have 2 patents for our products. - Our products are manufactured in China as per our specifications. - We have already been selling in a variety of stores in the USA since 2013. - We sell at 700 tractor supply stores, Orscheln Farm & Home, The Home Depot, Lowes, Zoro, Amazon, and Peavey. - Company has no liabilities and has a single owner. - Company has one employee and hires staff on demand based on the work. We have automated the process so it is easier to manage.

- 84-acre land in an industrial zone in New Albany, Indiana. - Property borders the Grant Line Industrial Park. - Land contains a 1,800 sq ft building. - Suitable for warehouse / distribution center, manufacturing facility, industrial park, and truck terminal.

- The company currently works with pharmaceutical and diagnostic companies, research institutes, CROs, and CDMOs to help them develop molecular bioassays and digital pathology products, and to visualize and analyze the resultant data via AI and ML for the benefit of patients, their family, and their healthcare providers. - Currently, has 3 clients: Klotho Therapeutics Inc. (a biotechnology company in San Diego, CA, USA), Unger Medical PC (a hair restoration medical practice in NY, NY, USA), and Astrix Technology Group (a life sciences strategy, technology, and staffing services company based in Red Bank, NJ, USA). • Target Market: - The business is specialized in developing diagnostics and therapeutics for human basal cell carcinoma, squamous cell carcinoma, and melanoma. This skin cancer group comprises the most diagnosed cancers worldwide of all cancer types with over five million cases diagnosed each year. - The skin cancer therapeutics diagnostics and therapeutics products industry worldwide were worth $8.2 billion USD in 2019 and is projected to reach $15 billion by 2027. This represents a CAGR of 7.5%. - What share of the total skin cancer target market can we estimate is realistic for to obtain? A conservative estimate is that our company should be able to reach $150 million USD in annual revenues by the close of 2028. • Problem or Need: - The main project involves the development of a Skin Cancer Patient Data Blockchain. - Currently there is a serious problem concerning how oncology patients organize and share their medical data, how companies get access to this data, and a lack of return in value to the patients for sharing their personal data. The blockchain is designed to tackle and solve these problems. - The blockchain for skin cancer patients will be comprised of multiple decentralized nodes contributing data to a shared ledger where patients can set up smart contracts to share and control their data. - Skin cancer patients will be able to share their data with research institutions, drug companies, diagnostic companies, contract research organizations, client trials organizers, and other stakeholders. - Also, planning to launch a medium of exchange within the blockchain system to allow patients to be given money for participation in the sharing of their data with the mentioned company stakeholders. - Therefore, the company stakeholders that plan to utilize the patient’s data would provide revenues and income to support the operations of the blockchain. - For example, pharmaceutical companies would be important customers that the business would cultivate as users of the patient’s healthcare data. This is because pharma companies can use this blockchain to discover patients with the right profile for a skin cancer clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. This should greatly streamline for the pharma company the time it takes to enroll the right patients into clinical trials and get them started. • Solution: - What is the core value proposition? For the company stakeholders in the skin cancer patient blockchain, the business is hoping to demonstrate that this blockchain technology will be a way to improve business outcomes through better efficiency, risk management, and security. - For these customers, this will enable them to maintain and capture new sources of profit. At the same time, company stakeholder participation will also grow the business as the integrator and host of the blockchain and result in significant profit growth for the company. • Team: The team is comprised of: - Founder, President, and CEO, a 100% full-time permanent employee has a Ph. D. in Cell and Molecular Biology from St. John’s University (New York, NY), a M. S. in Microbiology & Immunology from Long Island University, and a M. B. A. from Le Moyne College. In addition, he has 20 years of quality assurance and regulatory affairs experience at the Bristol-Myers Squibb Company, Charles Rivers Laboratories, and Vybion, Inc. This includes moving numerous human therapeutic products from R&D, through clinical trials, and into the marketplace via approval by the US FDA and worldwide regulatory bodies. In addition to the above experience, and an addition 18 year of experience in human therapeutics research and development and in the management of laboratory-based cell culture, toxicological, or bioassay projects within the biopharmaceuticals industry. However, he is a Senior Member of the food, drugs & cosmetics section of the American Society for Quality (ASQ), and a society member of The American Association for the Advancement of Science (AAAS). - The President of Hillberg Consulting is a part-time, non-permanent hourly contract employee of R&D department. She is an accomplished executive and board member with a reputation for delivering bottom-line profitability while building the infrastructure to support growth and success. She has served at Johnson & Johnson Ortho Clinical Diagnostics as VP of R&D, and as Chief Technology, Officer at Carestream Health. Holly has a B. S. in Chemical Engineering from Michigan Technology University and a M. S. in Electrical Engineering from Rochester Institute of Technology. - Marketing Consultant - part-time, non-permanent hourly employee. He is a professional engineer and entrepreneurial executive with focus on emerging technology solutions applied to real world problems. He has substantial experience in team building and in developing market strategies & partnerships. This includes over two decades of technology & networks business planning, development, & implementation. He has a Masters in Entrepreneurial Studies - MIT Sloan School of Management, and M. S. & B. S. in Engineering from Syracuse U. and Utica College. - Blockchain Development Technical Project Management Consultant - Part-time, non-permanent hourly employee that is a contractor from EffectiveSoft Corporation, San Diego, CA. She has eight years of experience as VP of Service Delivery and as the Head of Sales for enterprise level software solutions at Effective Soft Corp. She has a M. B. A. from The University of Manchester and a B. S. degree from Minsk State Linguistics U. – Legal Counsel - Part-time, non-permanent hourly contract employee. He holds the Juris Doctor from Boston College Law School, and B. A. in Political Science from Binghamton University. He is a Partner at Newman & Lickstein, with eight years of experience in representing technology companies and investors in licensing, IP development, real estate, mergers & acquisitions, and business litigation. - Demonstrating results to stakeholders will be the key to success. For skin cancer, there is a lot of data collected from various heterogeneous sources – pathology imaging data, genetic testing, surgery, drugs intervention, payer, and insurance information, etc. - Some companies are using a website or app to meet the social needs of patients to discuss their concerns with other patients or a few qualified physicians. No competitor is comprehensively focusing on skin cancer data & treatment to the level that we do. Possible competitors have thus not yet integrated the patient data, shared consent, and the patient monetization blocks together into a comprehensive and workable blockchain system for skin cancer patients, or for any segment of the oncology market, for that matter. - This team, on the other hand, has decades of experience in oncology research, the development of products and services for cancer patients, in oncology clinical biomedicine and in oncology marketing, and that makes the company well-equipped to solve the problems around skin cancer patient data acquisition, its organization, and its beneficial use for the patients and for their healthcare providers. For example, regarding the latter, the company also harnesses artificial intelligence (AI) and machine learning (ML) to extract relevant data from the patient’s database that will help healthcare providers to better understand the patient’s tumor and the tumor microenvironment (i. e. , tumor growth, cellular migration, blood supply to the tumor, subcellular trafficking, and tumor metastasis), drug efficacy (including drug penetration into the tumor, possible tumor shrinkage or tumor death, and drug toxicity, and side effects), or the immediate or long term results of surgical intervention. - When competitors enter this specific market, the business plans to stand out by utilizing a value-based strategy that clearly displays our brand and the above competitive advantage. • Traction: - Currently works with pharmaceutical and diagnostic companies, research institutes, and contract research development and manufacturing companies to help them obtain and organize their molecular bioassays and pathology data. We propose to utilize this traction and intercompany personal connections to gain and grow customers that will use and pay for patient data on the blockchain. - Also use social media & patient advocacy organization to recommend the blockchain to skin cancer patients so that we can grow the patient database. - The company is also a member of the Hyperledger Foundation Healthcare Special Interest Group. Hyperledger, as part of the Linux Foundation, provides technology leaders a uniquely open and collaborative international community from which to develop, validate, and field enterprise-grade blockchain technology solutions. It is the mandate of the Hyperledger Healthcare Special Interest Group (HC-SIG) to represent healthcare professionals and technologists, to globally unite these individuals, and to advance the state of the healthcare industry through the implementation of technology solutions using blockchain technologies in general, and the umbrella of Hyperledger frameworks and toolsets specifically. • Revenue Model: - Within the ecosystem surrounding the above patients, who would buy/lease the skin cancer blockchain services that the company wish to market? In this blockchain system, individuals will be allowed to store and monetize their own health data including blood test results, medical history, genetic profile, skin photographs, pathology images and other sensitive information. - In the healthcare marketplace, cancer patients would be paid in stablecoin currency to lease their individual data to companies for a certain amount of time. - Pharmaceutical (pharma) companies would be important customers that the company would cultivate as users of the patient’s permitted healthcare data. - Blockchain can help pharma companies discover patients with the right profile for a clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. - According to Milind Kamkolkar, chief data officer at Sanofi, patients could be prompted based on their data to join a clinical trial, thereby also accelerating the process and accuracy of trial recruitment. Using this blockchain if a person declines, no personal information will be shared, and the person's identity will remain private. If the person agrees, the overall process will move faster by abolishing the need for intermediaries. - For pharma companies, better inclusion in clinical trials and better reproducibility for studies can reduce the time and money needed to develop new drugs. - Besides pharma companies, research institutes will be willing to pay for the data from skin cancer patients, and the introduction of our blockchain-based data ecosystem may help ensure that the individuals take control over their data and companies and research institutions may acquire data more freely after the latter have obtained consent from individual patients. - How are the products and services going to generate revenue? The most straightforward way to generate revenue is to have the blockchain client customers pay for the products and services that exceeds by a large margin what it costs to develop and operate the blockchain (a cost-plus strategy). - When competitors enter this specific market, plan to stand out by utilizing a value-based strategy that clearly displays the brand and competitive advantage. • Market Projections: - What share of the total skin cancer blockchain target market can we estimate is realistic for to obtain? The global skin cancer blockchain customer market size stood at USD 8.19 billion in 2019 and is projected to reach USD 14.55 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period. A conservative estimate is that the company should be able to reach $150 million in annual revenues in 4 years. - These financial projections would be possible because of the company participating and partnering with individuals and companies within the oncology community to create superior value for the products and services. - Over the next 4 years, the company anticipates receiving funding from investors, and revenues from pharmaceutical companies and research institute customers. - However, expenditures are also expected to increase. Expenses incurred will be for the development of products and services, and for personnel, equipment, supplies, business development & marketing. • Competition: - Have identified Nebula Genomics and Longenesis as competition. These two leading firms in artificial intelligence and blockchain technology for healthcare, are developing a platform for the storage and exchange of genomic data. - Nebula Genomics is a San Francisco-based biotechnical company that uses blockchain to “build a marketplace” for clinical genetics data. - Longenesis is a Hong Kong-based partnership between Insilico Medicine and the Bitfury Group, which makes blockchain platforms for the exchange of health data. - The above companies will reportedly apply artificial intelligence and blockchain technology to develop a platform for individuals and large data providers to store, manage, exchange, and profit from genomic and other types of clinical data. To automate data acquisition, the project developed by both Nebula Genomics and Longenesis will utilize smart contracts. - Unlike the Nebula Genomics and Longenesis blockchains, this blockchain project will be focused on oncology patients and the ecosystem around them rather than on a multitude of disease sectors. - In addition to Nebula Genomics and Longenesis, the U. S. -based life science research marketplace, Scientist. com, has revealed the development of a pharmaceuticals blockchain platform. This latter blockchain-powered platform is reportedly designed to track and protect pharmaceutical data. Thus, the Scientist. com DataSmart TM platform enables pharmaceutical and biotech companies to demonstrate that critical supplier information and important research data has not been tampered with and remains unaltered before submission to regulators such as the FDA and the EMEA. - However, the above platforms do not adequately address the pressing concerns of cancer patients regarding the control and sharing of their personal data. Competitive Advantage: • Strategy. Specifically for oncology blockchain products, the major company players that may join our blockchain to gain access to data from skin cancer patients include: Almirall S. A. Amgen, Inc. Boehringer Ingelheim GmbH. Bristol-Myers Squibb Company. Eli Lilly and Company. Elekta AB. F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc. Merck & Co. , Inc. Mylan NV. Novartis AG. Pfizer. Regeneron. Sanofi. Sun Pharmaceutical Industries Ltd. Varian Medical Systems, Inc. Sensus Healthcare. ICAD, Inc. Accuray, Inc.

- We are a travel centre/truck stop startup business. - We provide various services in our centres. - The business already has 5 centres so far and is looking for investment for a new project. - This is a state-of-the-art travel centre to be built on a 43-acre parcel that has 45 car parking and 80 truck parking spaces with two national tenants. - The project details can be discussed over the phone or email.

- Company owns and operates a sawmill. - Promoter has 25 years of experience running businesses. - Features three complete sawmill production lines capable of producing 50 thousand board feet per day (MBFD): - Hurdle 1: 20 MBFD. - Hurdle 2: 20 MBFD. - Wood Mizer: 10 MBFD. - Facilities include metal buildings on concrete pads, a weighbridge, and office space. - Fully equipped with sufficient electrical power for uninterrupted operations. - Holds all necessary operating permits. - Major clients include construction companies and pallet manufacturers in the US Gulf Coast. - Currently in maintenance with production paused since January of this year; set to resume in a month. - Achieved a revenue of $2.6 million in the last fiscal year. - Looking to expand into the rail ties market, which promises higher revenue and EBITDA margins. - In our industry, the current employee count of 20 is sufficient to manage operations. - This transaction is listed by a family member based in India.

Both local and international trade is offered by us. Bringing in products from Panama, Colombia, and India. Moreover, with the potential to import items from Asia. Items sold in bulk across the United States. presently engaged in e-commerce and sales on Amazon. active in social media.

- The business is located in Grizzly Flats and operates in the contracting industry, focusing on construction, renovation, and repair in real estate, with a primary focus on residential projects and some commercial work. The business is operated on a 24 acre ranch with Gravel Roads a 3 acre lake with Island, a 1 Acre Pond with Island, 7 creeks, well, septic, Fiber optic internet, Cell tower within 2500'. There are places for hydroelectric power, meadows. There are historical artifacts from a town founded in 1850, as well as the "Old Wheeler Mine, " a gold mine. - The contractor is currently managing an average of 20 projects per year, with project durations ranging from a few days to a few months, depending on the size and scope of the project. - The current portfolio includes two spec home projects worth USD 500k each, reflecting a robust pipeline of potential revenue-generating opportunities. - The contractor is seeking an investment partner to facilitate a transition into semi-retirement and is offering a nearly 2-acre parcel of land as part of the partnership, with specific terms to be discussed. - The partnership opportunity includes the potential for the investor to be enrolled on the contractor's license, enabling them to take over the license without the typical prerequisites, offering a unique value proposition. - The business model emphasizes hands-on management and subcontracting, with a focus on securing and managing contracts for various projects, including fabricating, grading, sawmilling, excavation, home design, and real estate development. - The partnership aims to build and sell spec homes, with the goal of training the partner to take over the owner's license upon their retirement in a few years. - The partnership will initially focus on developing the 2-acre parcel and an additional 6-acre parcel owned by the business owner. - The owner is open to partnering with someone who may not have construction experience but should possess confident management skills. - The business owner plans to remain involved and assist in the projects, and there are opportunities for hydroelectric power and solar energy on the property anytime in the future. - Business has a CSLB license.